
|Videos|July 22, 2021
Vyluma pipeline focuses on refractive error
Advertisement
Vyluma, which recently spun off from Nevakar, has a robust pipeline for potential therapies addressing refractive error. Navneet Puri, PhD, the company’s founder, chairman, and CEO, offers additional insights.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement


















































.png)


